pemigatinib + gemcitabine + cisplatin

Pemigatinib + gemcitabine + cisplatin is a combination of three pharmaceutical drugs, each with a distinct mechanism of action, mainly investigated for the treatment of advanced or metastatic cholangiocarcinoma and other biliary tract cancers. Pemigatinib is a small molecule inhibitor targeting fibroblast growth factor receptors, particularly FGFR2, and is developed as a targeted therapy for tumors harboring FGFR2 rearrangements. Gemcitabine is a nucleoside analog that interferes with DNA synthesis, resulting in inhibition of cell proliferation, while cisplatin is a platinum-containing compound that disrupts DNA function by inducing DNA crosslinks and apoptosis. The combination is the subject of clinical research, but as of now is not recognized as a standard triple regimen; rather, pemigatinib is compared as a monotherapy against the standard gemcitabine plus cisplatin in clinical trials for the first-line treatment of unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangements[1][2][4][5]. There are limited or no data supporting the use of all three agents concurrently in clinical practice.